Parole chiave: Cell Therapy
, Extracellular Vesicles
, Liver Diseases
, Organ Printing
*** IBB - CNR *** Department of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, 10126 Turin, Italy. Maria Pia Hospital, 10126 Turin, Italy. Unit of Gastroenterology, Molinette Hospital, 10126 Turin, Italy. Institute of Biostructure and Bioimaging, National Research Council, Molecular Biotechnology Center, Via Nizza 52, 10126 Turin, Italy. firstname.lastname@example.org (V.C.) email@example.com (R.P.) firstname.lastname@example.org (B.Z.) email@example.com (L.S.) firstname.lastname@example.org (E.T.) email@example.com
Liver diseases represent a major global health issue, and currently, liver transplantation is the only viable alternative to reduce mortality rates in patients with end-stage liver diseases. However, scarcity of donor organs and risk of recidivism requiring a re-transplantation remain major obstacles. Hence, much hope has turned towards cell-based therapy. Hepatocyte-like cells obtained from embryonic stem cells or adult stem cells bearing multipotent or pluripotent characteristics, as well as cell-based systems, such as organoids, bio-artificial liver devices, bioscaffolds and organ printing are indeed promising. New approaches based on extracellular vesicles are also being investigated as cell substitutes. Extracellular vesicles, through the transfer of bioactive molecules, can modulate liver regeneration and restore hepatic function. This review provides an update on the current state-of-art cell-based and cell-free strategies as alternatives to liver transplantation for patients with end-stage liver diseases.<br>
29 Records (25 escludendo Abstract e Conferenze). Impact factor totale: 141.234 (121.039 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 145.606 (124.505 escludendo Abstract e Conferenze).